

The Mary Babb Randolph Cancer Center at West Virginia University
Scot C. Remick, MD, Director
invites candidates for

Clinical/Translational Investigator - Eminent Scholar¹ in Lung Cancer Research

The Mary Babb Randolph Cancer Center (MBRCC) of West Virginia University (WVU) seeks a distinguished clinical investigator and thought leader to further its clinical exploration and discovery targeting the prevention and cure of lung cancer. The selected candidate will exhibit extraordinary potential for taking new ideas from basic research and clinical practices to clinical trials for promising treatments for lung cancer; thus facilitating clinical development of novel agents and practices with laboratory methods for *in vivo* target assessment. He/she will have a solid background in clinical lung cancer research and be committed to bench-to-bedside activity, be comfortable with collaborative accomplishment, and have a willingness to share discoveries for the benefit of the larger medical community. The Eminent Scholar in Lung Cancer Research will hold a clinical faculty appointment in a department of the WVU School of Medicine dependent on discipline expertise and interests, with tenure-track appointment dependent on experience.

Unique opportunities exist in West Virginia for novel basic and clinical research investigations in lung cancer, with health disparities and risk factors well documented in populations targeted by MBRCC programs for clinical trials and state-wide clinical services. As a result, the MBRCC has experienced significant growth over the last 6 years and is funded for unprecedented future development in clinical research and patient care. With MBRCC's inter- and multi-disciplinary teams of more than 40 basic scientists, 60 clinicians, population scientists, and adjunct faculty from 7 Schools and 21 University Departments, there is exceptional opportunity to participate in robust, interdisciplinary translational research in a highly collaborative atmosphere. Guiding this unprecedented growth and development is renowned cancer researcher and physician Scot Remick, MD, who became Director of the Mary Babb Randolph Cancer Center in June, 2007. Reporting through faculty departmental lines in the School of Medicine with a coordinating relationship to the Director of the MBRCC, the Eminent Scholar in Lung Cancer Research will be provided substantial support to:

- Generate LOI concepts while maintaining a clinical practice focused on lung cancer;*
- Write clinical trials to maintain a growing, active extramural funded research program independently or collaboratively;*
- Participate as a member of multidisciplinary research teams bringing together basic scientists, translational researchers, and clinicians from many disciplines to translate findings from the bench to the bedside;*
- Work closely with the MBRCC Director and other leaders to expand existing lung cancer research efforts.*

The Eminent Scholar will have a substantial role in the translational lung cancer clinical research programs on the WVU campus, with its affiliates, as well as through interactions with leading national health agencies and companies in the region. Clinical duties are estimated at 2-3 days/week and inpatient service of 2-3 months/year. He/she will be expected to participate in translational research at the highest level with incentives related to: writing LOIs and investigator-initiated protocols; generating research revenue; enrolling patients on trials; and secondarily RVU generation. The Eminent Scholar will join the MBRCC and institutional leadership in helping maintain external relationships which contribute to the strategic leadership

¹ In 2007, the West Virginia State Legislature and Governor set aside significant funding to boost the research programs in WV. Initial resources of \$5.0 M/yr with \$2.5 M dedicated to the Mary Babb Randolph Cancer Center are provided for Eminent Scholars Recruitment and Enhancement, to increase the doctoral level workforce at WVU and elsewhere. More scholars with demonstrated research competitiveness will enable WV to compete successfully for a larger share of federal and foundation research funds; increase the creation of intellectual property, patenting and licensing; enhance WV universities' stature as vibrant, world-class research institutions; attract other talented faculty and graduate students to WV; foster new companies and create new collaborations with industry to commercialize technologies; and create economic opportunities and jobs for West Virginians.

and direction for translational lung cancer research. He/she will work as part of a team putting the MBRCC at the forefront of lung cancer research, treatment, and prevention locally, nationally, and internationally - leading to application for NCI designation in a few short years.

The successful candidate will be a highly skilled clinical/translational investigator at the junior or mid-level in his/her field, with MD or MD/PhD degrees and a solid track record of independent clinical research in lung cancer. This will be demonstrated by high quality publications in peer-reviewed journals and sustained extramural funding commensurate with years of experience. He/she will be motivated to promote a collaborative, interdisciplinary approach to lung cancer translational research, exhibit a willingness to build on the MBRCC's tradition of successful bench to bedside research, and present excellent communication and interpersonal skills. Preferred will be a candidate who: (1) can bring research funding with him/her to the MBRCC in order to continue an already well-established, relevant cancer-related clinical research agenda; and, (2) will complement current existing interests in our [research and clinical investigative programs](#), including but not limited to, signal transduction, tumor microenvironment, innovative radiographic imaging and detection technologies, and novel molecular prognostic/predictive biomarkers development. However, outstanding candidates from all other lung cancer research areas will be considered.

The [Mary Babb Randolph Cancer Center](#) is an inter- and a multi-disciplinary center which encompasses patient care, basic and clinical research, education, and outreach programs. This modern research and clinical facility, currently undergoing a 43,000sf expansion, contains patient care and research space which is centrally located within the comprehensive academic health sciences center complex known as the Robert C. Byrd Health Sciences Center. The MBRCC is West Virginia's most comprehensive cancer treatment, research, and education facility with more than 50,000 patient visits/year and over 2,000 hospital oncology admissions. It offers a multidisciplinary team approach and state-of-the-art technologies and treatments, as well as numerous clinical trials. The MBRCC's cancer clinic is operated by the [West Virginia University Hospitals, Inc.](#) and houses the Betty Puskar Breast Care Center and Comprehensive Breast Cancer Program; the Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program; the Blood and Marrow Transplant / Hematologic Malignancies Program – the only program of its kind offered in West Virginia; and NCI's Mid-Atlantic Cancer Information Service (CIS).

Founded in 1867, [West Virginia University](#) is one of only a limited number of public universities in the nation serving its state as both research and land-grant institutions. It is 1 of only 11 land-grant institutions offering a single health sciences campus with accredited Schools of Medicine, Dentistry, Nursing, and Pharmacy. As West Virginia's major research and development center and only comprehensive doctoral-granting institution, WVU faculty conduct research totaling over \$138 million in sponsored contracts and grants per year. The University's total operating budget is approximately \$749 million. The Carnegie Foundation for the Advancement of Teaching classifies WVU as a comprehensive doctoral institution with medical programs – placing it among only 50 such public and 28 private institutions nationwide; and when considering also the “high level of research activity,” WVU is again 1 of only 11 like institutions in the US.

Nominations, applications (including a cover letter, vitae, and list of 3 professional references), expressions of interest, requests for information, or confidential inquiries should be directed to:

Richard W. Phalunas, EdD, President
The Brooke Group
304.594.1890 / rphalunas@mrinet.com